Reaction
Ureterolithiasis reporting signals
As of the last recalculation, Ureterolithiasis appears in 1,032 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is FEBUXOSTAT TABLETS 40 MG (PRR 20.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Febuxostat Tablets 40 Mg | 10 | 20.0 | 20.0 |
| Febuxostat Tablets 80 Mg | 10 | 20.0 | 20.0 |
| Teduglutide | 12 | 18.2 | 18.2 |
| Gentamicin | 10 | 15.6 | 15.6 |
| Hydroxyurea | 15 | 14.5 | 14.5 |
| Febuxostat | 10 | 12.1 | 12.1 |
| Pitavastatin Calcium | 6 | 11.9 | 11.9 |
| Dolutegravir Sodium | 5 | 11.2 | 11.2 |
| Rasagiline Mesylate | 6 | 10.9 | 10.9 |
| Emtricitabine And Tenofovir Alafenamide | 5 | 8.9 | 8.9 |